Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma
Open Access
- 8 October 2003
- Vol. 98 (10) , 2192-2198
- https://doi.org/10.1002/cncr.11790
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III TrialJournal of Clinical Oncology, 1999
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate CancerJournal of Clinical Oncology, 1999
- Graft-Versus-Tumor Induction With Donor Leukocyte Infusions as Primary Therapy for Patients With MalignanciesJournal of Clinical Oncology, 1999
- Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinomaAnnals of Oncology, 1999
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- Prostate cancerCurrent Opinion in Oncology, 1997
- Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell linesPublished by Wiley ,1997